# Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

> **NCT03778073** · PHASE1 · TERMINATED · sponsor: **TG Therapeutics, Inc.** · enrollment: 18 (actual)

## Conditions studied

- B-cell Non Hodgkin Lymphoma
- Richter's Transformation

## Interventions

- **DRUG:** Cosibelimab
- **DRUG:** Cosibelimab + Ublituximab + Bendamustine combination
- **DRUG:** Cosibelimab + Ublituximab + Bendamustine combination

## Key facts

- **NCT ID:** NCT03778073
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-17
- **Primary completion:** 2022-05-03
- **Final completion:** 2022-08-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Strategic/Business Decision
- **Last updated:** 2022-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03778073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03778073, "Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03778073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*